Genentech Avastin launch timeline
Genentech is producing Avastin in anticipation of approval of the colorectal cancer therapy by its March 31 user fee date. However, the company has not begun putting the product into commercial dosage forms, which could cause launch to be delayed by at least one month. [Editor's Note: More coverage the Avastin launch timeline will appear in 1"The Pink Sheet" DAILY. Visit our website, www.ThePinkSheetDAILY.com, to sign up for a free trial.]...
You may also be interested in...
Genentech and FDA are in negotiations over final labeling and Phase IV commitments.
Court finds US FDA did not impede Catalyst orphan exclusivity for Firdapse as it approved different indication for competing product. Biogen loses 10-year patent battle against competing multiple sclerosis drug makers.
Cover Three Nutritional Brain Defense marketer agrees to pull claims suggesting the supplement beverage can protect against traumatic brain injury after a test the firm on DHA submitted as support contained considerably higher levels of the ingredient than included in the product.